Home | Welcome to Contract Pharma   
Last Updated Wednesday, September 17 2014
Print

Financial Report: Alexion



Published April 24, 2014
Alexion
 
1Q Revenues: $566.6 million (+67%)

1Q Earnings: $159.4 million (+94%)

Comments: Solaris sales were $566.6 million, up 67%, which included $87.8 million in reimbursements of prior year shipments related to an agreement with the French government. Sales also include additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). R&D expenses were $191.5 million, up from $74.5 in 1Q13.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On